Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer
Breast cancer is the most common form of cancer in women and its incidence has been increasing over the years. Human epidermal growth factor receptor 2 (HER2 or ErbB2) overexpression is responsible for 20 to 25% of invasive breast cancers, and is associated with poor prognosis. HER2-targeted therapy...
Main Authors: | ZiYan Yang, Wei Wang, Xiaojia Wang, ZhiQuan Qin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.741451/full |
Similar Items
-
The Signaling of Neuregulin-Epidermal Growth Factor Receptors and Its Impact on the Nervous System
by: Marzia Tagliaferro, et al.
Published: (2023-10-01) -
Airway Epithelial Dysfunction in Asthma: Relevant to Epidermal Growth Factor Receptors and Airway Epithelial Cells
by: Hideki Inoue, et al.
Published: (2020-11-01) -
Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer
by: Qing Ye, et al.
Published: (2017-01-01) -
Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: predictive factors and survival
by: RODRIGO VIEIRA GOMES, et al.
Published: (2018-07-01) -
ErbB polymorphisms: Insights and implications for response to targeted cancer therapeutics
by: Moulay A Alaoui-Jamali, et al.
Published: (2015-02-01)